IGF2 induces CD133 expression in esophageal cancer cells to promote cancer stemness
Failure to eradicate cancer stem cells (CSC) during primary therapy may lead to cancer recurrence. We recently reported that CD133 is a functional biomarker for CSCs in esophageal squamous cell carcinoma (ESCC) but the molecular pathways critical for maintenance of CD133-positive CSCs are largely unknown. Here, we revealed that knockdown of IGF2 or treatment with PI3K/AKT inhibitors markedly inhibited the abilities of CD133-positive ESCC cells to self-renew, resist chemotherapeutic drugs, and form tumors.
Source: Cancer Letters - Category: Cancer & Oncology Authors: Wen Wen Xu, Bin Li, Jian Fu Zhao, Jing Ge Yang, Jun Qi Li, Sai Wah Tsao, Qing-Yu He, Annie L.M. Cheung Tags: Original Articles Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Esophagus Cancer | Skin Cancer | Squamous Cell Carcinoma | Stem Cell Therapy | Stem Cells